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Abstract: Patients undergoing knee joint replacement (KJR) are at high risk of postoperative venous
thromboembolism (VTE), but data on the time trends of VTE rate in this population are sparse. In
this analysis of the German nationwide inpatient sample, we included all hospitalizations for elective
primary KJR in Germany 2005-2016. Overall, 1,804,496 hospitalized patients with elective primary KJR
(65.1% women, 70.0 years [IQR 63.0-76.0]) were included in the analysis. During hospitalization, VTE
was documented in 23,297 (1.3%) patients. Total numbers of primary KJR increased from 129,832 in
2005 to 167,881 in 2016 (฀-(slope)-estimate 1,978 [95% CI 1,951 to 2,004], P < 0.001). In-hospital VTE
decreased from 2,429 (1.9% of all hospitalizations for KJR) to 1,548 (0.9%) cases (฀-estimate - 0.77 [95%
CI - 0.81 to - 0.72], P < 0.001), and in-hospital death rate from 0.14% (184 deaths) to 0.09% (146 deaths)
(฀-estimate - 0.44 deaths per year [95% CI - 0.59 to - 0.30], P < 0.001). Infections during hospitalization
were associated with a higher VTE risk. VTE events were independently associated with in-hospital
death (OR 20.86 [95% CI 18.78-23.15], P < 0.001). Annual number of KJR performed in Germany
increased by almost 30% between 2005 and 2016. In parallel, in-hospital VTE rates decreased from 1.9
to 0.9%. Perioperative infections were associated with higher risk for VTE. Patients who developed VTE
had a 21-fold increased risk of in-hospital death.
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Venous thromboembolism 
in patients hospitalized for knee 
joint replacement surgery
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Thomas Münzel1,5, Martin Engelhardt6,7, Lukas Eckhard8, Stavros V. Konstantinides2,9 & 
Philipp Drees8
Patients undergoing knee joint replacement (KJR) are at high risk of postoperative venous 
thromboembolism (VTE), but data on the time trends of VTE rate in this population are sparse. In 
this analysis of the German nationwide inpatient sample, we included all hospitalizations for elective 
primary KJR in Germany 2005–2016. Overall, 1,804,496 hospitalized patients with elective primary 
KJR (65.1% women, 70.0 years [IQR 63.0–76.0]) were included in the analysis. During hospitalization, 
VTE was documented in 23,297 (1.3%) patients. Total numbers of primary KJR increased from 129,832 
in 2005 to 167,881 in 2016 (β-(slope)-estimate 1,978 [95% CI 1,951 to 2,004], P < 0.001). In-hospital 
VTE decreased from 2,429 (1.9% of all hospitalizations for KJR) to 1,548 (0.9%) cases (β-estimate 
− 0.77 [95% CI − 0.81 to − 0.72], P < 0.001), and in-hospital death rate from 0.14% (184 deaths) to 
0.09% (146 deaths) (β-estimate − 0.44 deaths per year [95% CI − 0.59 to − 0.30], P < 0.001). Infections 
during hospitalization were associated with a higher VTE risk. VTE events were independently 
associated with in-hospital death (OR 20.86 [95% CI 18.78–23.15], P < 0.001). Annual number of KJR 
performed in Germany increased by almost 30% between 2005 and 2016. In parallel, in-hospital VTE 
rates decreased from 1.9 to 0.9%. Perioperative infections were associated with higher risk for VTE. 
Patients who developed VTE had a 21-fold increased risk of in-hospital death.
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RDC  Research data center
VTE  Venous thromboembolism
Knee joint replacement (KJR) surgery is one of the most common orthopedic procedures currently performed 
in the ageing populations of Western  countries1. In the year 2010, the number of KJR procedures performed in 
the United States increased to more than 700,000 per  year2. It has been foreseen that this number will further 
grow to approximately 3.5 million KJR procedures by the year  20302. Although this operation is one of the most 
successful and life-changing interventions available  today1 and can substantially improve mobility and quality 
of life, these patients are characterized by high risk for perioperative venous thromboembolism (VTE), present-
ing as deep vein thrombosis and/or pulmonary embolism (PE), even in the era of established pharmacological 
 thromboprophylaxis1–6. The release of thromboplastins from the dissected soft tissue and reamed bone, as well as 
venous stasis both initiated during surgery and the postoperative immobility, provoke a high rate of VTE  events1.
Without thromboprophylaxis, the rate of proximal deep vein thrombosis after KJR surgery was reported to be 
between 5 and 22%, that of PE of 1.5–10%2,6,7. This risk can be reduced substantially by the use of pharmacologi-
cal thromboprophylaxis and with a three-month cumulative incidence of symptomatic VTE falling to 2.3%2,8.
With increasing numbers of KJR procedures in western  countries2,6,9–11, the number of VTE events is expected 
to  rise2,6. Actual data about temporal trends regarding total numbers of performed KJR and particularly the 
impact of VTE on in-hospital mortality of KJR patients is sparse. This knowledge for optimizing secondary pre-
vention strategies in this patient population. Thus, the aims of our study were to investigate, (a) temporal trends 
in the total numbers of KJR performed in Germany between 2005 and 2016, including trends in the patients’ age 
as well as comorbidities; (b) the total burden and temporal trends of VTE complications following KJR; (c) the 
impact of VTE on mortality rates in KJR patients; and (d) predictors of VTE during hospitalization.
Results
A total of 1,804,496 hospitalizations were recorded for elective (primary) KJR in Germany from 2005 to 2016 and 
were included in the present analysis (see Fig. S1 in the supplementary material for study flow chart). Among 
these, the majority of patients hospitalized (65.1%) were women, and 53.4% were 70 years or older (median 
70.0 years [IQR 63.0–76.0]). The estimated average crude annual incidence of elective primary KJR was 221.0 
KJR per 100,000 population-years during this time period.
Temporal trends of primary surgical knee joint replacements, patients’ baseline character-
istics and in-hospital events. The total number of KJR performed as well as in-hospital death rates 
increased substantially with age (Fig. 1A). While men were more frequently represented than women in the first 
three decades of life, the proportion of women was higher among patients aged 30 years and older (Fig. S2C in 
the supplementary material).
The total number of patients who underwent KJR in Germany increased from 129,832 in the year 2005 to 
167,881 in 2016 (β-(slope)-estimate 1,978 [95% CI 1,951 to 2,004] increase per year, P < 0.001). A total of 2,112 
patients undergoing elective primary KJR died during the in-hospital stay for an overall perioperative death rate 
of 0.1%. The crude annual in-hospital death rate decreased from 0.14% (184 deaths) to 0.09% (146 deaths) of 
KJR-related hospitalizations (β-estimate − 0.4 deaths per year [95% CI − 0.6 to − 0.3], P < 0.001) over the time 
period studied (Fig. 1B, Table S2 in the supplementary material). The median duration of hospitalization for 
KJR decreased from 15 (13–16) days in 2005 to 10 (8–12) in 2016 (β-estimate − 0.12 [95% CI − 0.12 to − 0.12], 
P < 0.001) (Fig. 2A) and was primarily depending on patients’ age (Fig. S3 in the supplementary material).
The proportion of patients aged 70 years or older among those who underwent KJR, decreased from 54.0% 
in 2005 to 50.3% in 2016 (β-estimate − 0.14 [95% CI − 0.15 to − 0.13], P < 0.001). In parallel, the prevalence of 
some important comorbidities such as cancer and coronary artery disease decreased during the same timeframe 
(Fig. S2B + C, Fig. S4 and Table S1 in the supplementary material). Although females outweighed male patients 
with regard to KJR performed throughout the entire study period, the proportion of male patients increased 
slightly over time (Fig. S2A and Table S1 in the supplementary material). The rate of myocardial infarction, 
stroke, intracerebral bleeding complications as well as necessity of transfusions of blood constituents decreased 
(Fig. 2B + C, Fig. S5 and Table S2 in the supplementary material).
Thromboembolic complications in patients undergoing elective knee joint replacement. A 
VTE event was recorded in 23,297 (1.3%) patients during hospitalization, presenting as deep venous thrombosis 
or thrombophlebitis (DVT) in 19,535 (83.9%) and of PE in 5,040 (21.6%) cases. Importantly, haemodynamic 
instability was recorded in 10.9% of the patients who suffered acute PE in-hospital. VTE events and consistently 
its subentities decreased over time. While 2,429 (1.9%) patients operated for KJR suffered VTE in hospital in the 
year 2005, only 1,548 (0.9%) VTE were recorded in 2016 (β-estimate − 0.77 [95% CI − 0.81 to − 0.72], P < 0.001). 
The rate of DVT (1.6% in 2005 to 0.8% in 2016; β-estimate − 0.82 [95% CI − 0.87 to − 0.77], P < 0.001) and PE 
(0.4% in 2005 to 0.2% in 2016; β-estimate − 0.52 [95% CI − 0.61 to − 0.42], P < 0.001) were reduced by almost 
50% (Fig. 1 and Table S2 in the supplementary material). The number of VTE events increased with the patients’ 
age (β 0.14 [0.12 to 0.15], P < 0.001) (Fig. 1A).
Patients undergoing primary KJR who suffered VTE during hospitalization were more often women (72.5% 
vs. 65.0%, P < 0.001), older (72.0 [65.0–77.0] vs. 70.0 [63.0–76.0] year, P < 0.001), and more often obese (27.9% 
vs. 22.9%, P < 0.001) compared to those without VTE (Table 1). Typical risk factors for thrombosis such as 
cancer (1.4% vs. 0.8%, P < 0.001) and thrombophilia (whenever sought and detected; 0.3% vs. 0.1%, P < 0.001), 
were more prevalent in patients with VTE. Patients with VTE more frequently revealed cardiovascular, renal 
and respiratory comorbidities (Table 1). In-hospital infections such as pneumonia (2.8% vs. 0.3%, P < 0.001), 
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urinary tract infections (5.2% vs. 2.8%, P < 0.001), and sepsis (0.26% vs. 0.04%, P < 0.001) all were more often 
recorded in association with VTE. Finally, myocardial infarction (0.6% vs. 0.2%, P < 0.001) and stroke (0.6% vs. 
0.2%, P < 0.001) also were more frequently reported in patients with VTE (Table 1). The rate of infectious com-
plications remained largely unchanged over time (Figures S5 as well as Table S2 in the supplementary material). 
At multivariable analysis, cancer, heart failure as well as infections such as sepsis, pneumonia, and urinary tract 
infection were independently associated with VTE events during the hospital stay (Table 2).
In patients undergoing primary KJR, the risk of death was 22-fold higher if they suffered VTE compared 
to patients without VTE (2.2% vs. 0.1%, P < 0.001) (Table 1). In the logistic regression models, VTE increased 
the risk of dying during hospitalization univariably (OR 25.65 [95% CI 23.22–28.34], P < 0.001), but also inde-
pendently from age, sex and comorbidities (OR 20.86 [95% CI 18.78–23.15], P < 0.001). The impact of VTE on 
in-hospital varied annually (Table S3 in the supplementary material). In addition, we analysed the total numbers 
of in-hospital deaths in patients undergoing primary KJR at each day of hospitalization (day 1–15) and the 
proportion of deaths, which were related to prior VTE events during hospitalization at each day. The propor-
tion of VTE related death was highest at the first 7 days after admission and decreased over the hospitalization 
period (Fig. 3). As expected, bleeding complications such as intracerebral and gastrointestinal bleeding as well 
as transfusions of blood components were more often detected in KJR patients with VTE (Table 1). The rate 
of VTE and bleeding complications remained low and decreased over time, as did the need for transfusions of 
blood constituents (Figs. 2C and 3C as well as Table S2 in the supplementary material). The length of in-hospital 
stay was in median 12.0 days (IQR 10.0–14.0) and was longer in patients with (14 [12–18]) vs. without (12 
[10–14] days) VTE (P < 0.001; Table 1). VTE occurrence was associated with hospitalization longer than 14 days 
(crude: OR 3.09 [95% CI 3.01–3.18], P < 0.001]; adjusted model: OR 3.09 [95% CI 3.00–3.18], P < 0.001). This 
result remained stable after additional adjustment for the year of hospitalization (OR 3.11 [95% CI 3.02–3.20], 
P < 0.001). Nevertheless, the impact of VTE regarding prolonged hospitalization increased slightly over time 
(Table S4 in the supplementary material).
Figure 1.  Time trends in absolute number of hospitalizations, in-hospital mortality and VTE rate in patients 
undergoing elective primary KJR in Germany from 2005 to 2016. (A) Total numbers of patients undergoing 
elective primary KJR (grey bars) and in-hospital death rate (orange line), stratified per decade of age, over the 
entire period 2005–2016 (cumulative data). (B) Annual total numbers of patients undergoing elective primary 
KJR (grey bars) and corresponding annual in-hospital death rates (orange line) in Germany in the period 2005–
2016. (C) Percentage of patients undergoing elective primary HJR who developed in-hospital VTE (light blue 
bars); the panel further shows percentage of deep vein thrombosis and thrombophlebitis (DVT, light blue line), 
pulmonary embolism (PE, admiral blue line), and high-risk PE with hemodynamic instability (dark blue line).
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Discussion
VTE, with its clinical manifestations of DVT and PE, is responsible for significant morbidity and mortality in 
Europe and  worldwide5,12. Important major provoking risk factors of VTE are represented by orthopaedic-related 
issues, notably major trauma and surgery, lower-limb fracture, joint replacement, and spinal cord  injury5.
Our study results demonstrate an increasing demand and rising annual numbers of performed KJR in the 
aging western populations, in line with what described in other high-income  states2,6,8–11. These temporal trends 
regarding total numbers of KJR and perioperative complications are important for adequate management of pub-
lic health as well as health care service planning. Although KJR can substantially improve patients` mobility and 
quality of life in patients with advanced gonarthritis, it is accompanied by a high risk of  VTE2,13–16. While without 
thromboprophylaxis, the rate of DVT in screening examinations in patients undergoing KJR was reported as 
approximately 60% (including symptomatic as well as asymptomatic DVT events)13,14, the risk of VTE after KJR 
can be significantly decreased by the use of pharmacological  thromboprophylaxis2. In accordance with results 
from studies of KJR conducted in other states reporting a 1.1% in-hospital VTE rate after  KJR17, we identified an 
in-hospital VTE rate of 1.3% in patients undergoing elective KJR in Germany. Importantly for adequate health 
care planning, the VTE rate decreased significantly from 1.9% in 2005 to 0.9% in 2016. This favorable trend 
may be due to several factors, including the introduction of the direct oral anticoagulants, the decrease in the 
use of tourniquets and/or surgical time of tourniquet use, a small increase in the number of uncemented KJR 
 procedures18, the incline in unicondylar  KJR18, decreasing age and the introduction of fast-track procedures 
improving early mobilization and  discharge19,20.
Current practice guidelines provide partly conflicting recommendations for the medical VTE prophylaxis 
after  KJR21,22. Additionally, the appropriate duration of anticoagulation following elective KJR is highly contro-
versial and a dynamically evolving topic. Country-specific guideline recommendations as well as physicians’ and 
patients’ preferences, have a major impact on the management strategies. While the German AWMF guidelines 
recommend low-molecular weight heparins (LMWH), fondaparinux or novel oral anticoagulants (NOAC) at 
a prophylactic dose for 11–14 days after  KJR22, the National Institute of Health and Care Excellence guidelines 
(NICE) in the United Kingdom recommend LMWH, or NOACs, with aspirin recommended for extended 
 prophylaxis21,23. The guidelines of the American College of Chest Physicians and the American Association of 
Orthopaedic Surgeons recommend LMWH, (N)OACs or  aspirin3,6,7,21,24.
There is still a great controversy about the effect of tourniquets on development of VTE after  KJR25–28. The use 
of a tourniquet improves visualization during KJR surgery and may shorten the operating  time28. However, there 
Figure 2.  Time trends in length of hospitalization and rates of serious complications in patients undergoing 
elective primary KJR in Germany from 2005 to 2016. (A) Median duration of hospitalization (solid black 
line) with 25% and 75% IQR (dashed black lines). (B) Percentage of patients developing shock (dark blue 
bars) and undergoing cardio-pulmonary resuscitation (CPR, light blue bars) out of all patients undergoing 
elective KJR. (C) Percentage of patients with bleeding events such as intracerebral bleeding (ICB, light red 
bars), subarachnoid bleeding (SAB, dark red bars) and gastrointestinal bleeding (GIB, orange bars) as well as 
necessitation for transfusions of blood constituents (red line) out of all patients undergoing elective KJR.
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is also some evidence that the use of tourniquet during KJR surgery may lead to increased numbers of  DVT25–28. 
Furthermore, previous studies have reported that cemented fixation as compared to cement-less fixation was 
found as a risk factor for VTE in hip and  KJR29,30; nevertheless, the role of cement as a thrombogenic agent and 
cause of emboli during or after joint replacements is not entirely clear to  date30–32. In Germany more than 90% 
of the KJR were operated with cement  fixation18. Finally, the decreasing proportion of VTE in KJR patients 
may partly be explained by trends regarding patients’ age during the observational period. It is known that the 
incidence of VTE grows exponentially with  age33–35. The proportion of patients aged ≥ 70 years decreased from 
2005 to 2016, and this may have contributed to the decrease of the proportion of VTE events in KJR.
We confirmed the role of relevant predictors of VTE, such as  age19,36,37,  cancer37, female  gender38,  obesity37,39 as 
well as heart  failure37,40,  AF41, peripheral artery  disease42,  COPD43,44, and renal  insufficiency45. In addition, acute 
cardiovascular events during hospitalization for elective KJR such as myocardial  infarction40,46 and  stroke37,47, 
but also  infections48 occurring during hospitalization were significantly associated with VTE development, 
although our study design does not permit speculation about cause and effect. In fact, our results demonstrated 
that systemic infectious diseases (pneumonia and sepsis) were accompanied with a higher VTE risk than tra-
ditional VTE risk factors like cancer and thrombophilia. VTE events in patients undergoing primary KJR were 
associated with a significant 3.1-fold risk of prolonged hospitalization (beyond 14 days).
Our study highlights that perioperative VTE events aggravate the early prognosis of patients operated at the 
knee joint: perioperative VTE events were associated with a 21-fold increased risk of in-hospital deaths indepen-
dently from age, sex and comorbidities. In parallel with reduction of VTE events, the KJR patients’ in-hospital 
mortality decreased from 2005 to 2016. In addition, we detected a decreasing rate of periprocedural myocardial 
infarction, stroke and major bleeding, which might have contributed to this mortality reduction.
Although the median duration of hospitalization for elective KJR decreased from 15 days in the year 2005 
to 10 days in the year 2016, the median length of stay in the year 2016 was still substantially longer in Germany 
than in the United Kingdom (6 days in regular medical care and 3 days for enhanced recovery programs)49 or 
in the United States (4 days)50. In other European countries, enhanced recovery protocols have been adopted, 
resulting in short length of hospitalization of only 2 days (in median)20. Interestingly, enhanced recovery with 
halved length of in-hospital stay was accompanied by lower rate of cardiac ischemic events and lower mortality 
rate at 30 and 90 days follow-up after KJR and hip joint  replacement49.
Table 1.  Patient characteristics of 1,804,496 patients with elective KJR. *Data available for 1,804,428 patients.
Parameters
Patients without VTE
(n = 1,781,199; 98.7%)
Patients with VTE
(n = 23,297; 1.3%) P-value
Age 70.0 (63.0–76.0) 72.0 (65.0–77.0)  < 0.001
Age ≥ 70 years 950,241 (53.3%) 13,806 (59.3%)  < 0.001
Female gender * 1,156,887 (65.0%) 16,894 (72.5%)  < 0.001
In-hospital stay (days) 12 (10–14) 14 (12–18)  < 0.001
Obesity 407,073 (22.9%) 6,507 (27.9%)  < 0.001
Comorbidities
Cancer 14,279 (0.8%) 336 (1.4%)  < 0.001
Coronary artery disease 162,093 (9.1%) 2,650 (11.4%)  < 0.001
Chronic heart failure 99,546 (5.6%) 2,340 (10.0%)  < 0.001
Peripheral artery disease 14,900 (0.8%) 283 (1.2%)  < 0.001
Atrial fibrillation/flutter 103,603 (5.8%) 1,954 (8.4%)  < 0.001
Chronic obstructive pulmonary disease 62,079 (3.5%) 1,122 (4.8%)  < 0.001
Essential arterial hypertension 1,058,340 (59.4%) 14,101 (60.5%) 0.001
Acute and chronic renal failure 99,552 (5.6%) 1,955 (8.4%)  < 0.001
Diabetes mellitus 305,510 (17.2%) 4,164 (17.9%) 0.004
Thrombophilia 1,810 (0.1%) 67 (0.3%)  < 0.001
In-hospital conditions/outcomes
In-hospital death 1,590 (0.1%) 522 (2.2%)  < 0.001
Pneumonia 5,448 (0.3%) 649 (2.8%)  < 0.001
Sepsis 651 (0.04%) 60 (0.26%)  < 0.001
Urinary tract infection 50,497 (2.8%) 1,206 (5.2%)  < 0.001
Shock 2,008 (0.1%) 214 (0.9%)  < 0.001
Cardio-pulmonary resuscitation 1,915 (0.1%) 492 (2.1%)  < 0.001
Myocardial infarction 3,139 (0.2%) 147 (0.6%)  < 0.001
Stroke 2,752 (0.2%) 147 (0.6%)  < 0.001
Intracerebral bleeding 108 (0.01%) 8 (0.03%)  < 0.001
Gastro-intestinal bleeding 1,704 (0.1%) 77 (0.3%)  < 0.001
Transfusion of blood constituents 209,484 (11.8%) 4,849 (20.8%)  < 0.001
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Table 2.  Association of patients’ characteristics and in-hospital events with occurrence of VTE (univariate 
and multivariable logistic regression models). *Adjusted for age, sex, obesity, cancer, coronary artery disease, 
heart failure, atrial fibrillation/flutter, arterial hypertension, chronic obstructive pulmonary disease, acute and 




OR (95% CI) P-value OR (95% CI) P-value
Age 1.02 (1.01–1.02)  < 0.001 1.01 (1.01–1.01)  < 0.001
Age ≥ 70 years 1.27 (1.24–1.31)  < 0.001 1.19 1.16–1.22)  < 0.001
Female gender * 1.42 (1.38–1.47)  < 0.001 1.40 (1.36–1.45)  < 0.001
Obesity 1.31 (1.27–1.35)  < 0.001 1.31 (1.27–1.35)  < 0.001
Comorbidities
Cancer 1.81 (1.62–2.02)  < 0.001 1.82 (1.63–2.03)  < 0.001
Coronary artery disease 1.28 (1.23–1.34)  < 0.001 1.15 (1.11–1.20)  < 0.001
Chronic heart failure 1.89 (1.81–1.97)  < 0.001 1.53 (1.46–1.61)  < 0.001
Peripheral artery disease 1.46 (1.30–1.64)  < 0.001 1.29 (1.15–1.46)  < 0.001
Atrial fibrillation/flutter 1.48 (1.42–1.55)  < 0.001 1.26 (1.20–1.32)  < 0.001
Chronic obstructive pulmonary disease 1.40 (1.32–1.49)  < 0.001 1.24 (1.17–1.32)  < 0.001
Essential arterial hypertension 1.05 (1.02–1.08) 0.001 0.95 (0.93–0.98)  < 0.001
Acute and chronic renal failure 1.55 (1.48–1.62)  < 0.001 1.26 (1.20–1.33)  < 0.001
Diabetes mellitus 1.05 (1.02–1.09) 0.004 0.95 (0.92–0.99) 0.005
Thrombophilia 2.84 (2.22–3.62)  < 0.001 2.83 (2.22–3.62)  < 0.001
In-hospital conditions
Pneumonia 9.34 (8.60–10.14)  < 0.001 7.21 (6.61–7.85)  < 0.001
Sepsis 7.06 (5.42–9.20)  < 0.001 5.16 (3.94–6.75)  < 0.001
Urinary tract infection 1.87 (1.77–1.98)  < 0.001 1.57 (1.48–1.66)  < 0.001
Myocardial infarction 3.60 (3.05–4.25)  < 0.001 2.61 (2.20–3.09)  < 0.001
Stroke 4.10 (3.47–4.85)  < 0.001 3.50 (2.96–4.14)  < 0.001
Figure 3.  Time trend regarding cumulative number of deaths during the hospitalization period in patients 
undergoing elective primary KJR in Germany from 2005 to 2016. Total numbers of in-hospital deaths at the 
different hospitalization days (black bars), in-hospital deaths of patients undergoing elective primary KJR with 
VTE (green bars) and proportion of deaths in conjunction with VTE. Only the in-hospital deaths of the first 
15 days after admission were taken into account.
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Recent studies of nationwide cohorts reported that patients treated according these protocols had a low 
90-day VTE rate of 0.39%20. The results of these mentioned studies contributed to fuel the discussion on whether 
prolonged pharmacological thromboprophylaxis (after discharge from hospital) is beneficial and needed for all 
patients treated with an enhanced recovery protocol and hospitalized for a period of 5 days or  shorter19,20. In 
these patients, a preventive strategy based on in-hospital thrombo-prophylactic treatment with the Factor Xa 
inhibitor rivaroxaban followed by low-dose aspirin appeared to be effective and safe for  thromboprophylaxis50. 
These results remain to be confirmed in other countries, in which fast-track surgery and enhanced recovery 
protocols will be introduced or were introduced more  recently21.
The key strength of our present analysis of the German nationwide inpatient sample is the very large number 
of unselected patients undergoing KJR, presenting real-world and practice-based data without selection bias. 
On the other hand, since our study results are based on ICD discharge codes and OPS diagnostic, procedural 
and/or surgical coding, it has to be mentioned that misclassification of clinical events, underestimation of event 
rates driven by underreporting or undercoding by the hospital personnel cannot be excluded. Additionally, we 
could not analyze any possible repeated hospitalizations of the same patient. A further limitation of our study is 
the focus on the in-hospital period without assessment of events after discharge, which may also potentially lead 
to an underestimate of the total number of postoperative VTE events. Due to coding reasons, we were not able 
to distinguish between unilateral and bilateral KJR. Nevertheless, it has been published that the proportion of 
bilateral KJR during one hospitalization is < 4% in  Germany51. Neither prior VTE, nor anticoagulant, antiplatelet 
treatment or tranexamic acid use were assessed in the German nationwide inpatient sample. Thus, the potential 
impact of these factors on occurrence of VTE after KJR could not be analyzed, which has to be mentioned as a 
further limitation of our  study52. As per routine clinical practice, venous ultrasound to diagnose DVT was pri-
marily performed in symptomatic patients. It must be considered that the results from the German nationwide 
sample may not be generalizable for other geographic regions, countries, and health systems.
In conclusion, perioperative VTE was recorded in 1.3% of the KJR patients during hospitalization. While 
the number of KJR increased in Germany from 2005 to 2016, the rate of VTE events decreased from 1.9% in 
the year 2005 to 0.9% in 2016. VTE events in patients undergoing primary elective KJR were associated with a 
21-fold risk of in-hospital death rates and a 3.1-fold risk for prolonged hospitalization.
Patients and methods
Data source. The analyses of our study were run on our behalf by the Research Data Center (RDC) of the 
Federal Statistical Office and the Statistical Offices of the federal states in Wiesbaden, Germany (source: RDC 
of the Federal Statistical Office and the Statistical Offices of the federal states, DRG Statistics 2005–2016, own 
calculations). Priorly, we had provided the created SPSS scripts to the RDC. After computing the analyses by 
the RDC, we received the aggregated results of the statistics (SPSS software, version 20.0, SPSS Inc., Chicago, 
Illinois). For this study, we selected and included all surgical patients with elective primary KJR hospitalized in 
the timeframe between January 2005 and December 2016 in German hospitals. Since we intended to focus only 
on hospitalized patients with elective primary procedures, we excluded patients with acute fractures. The study 
flow was described in part  previously53–56. The study results are not part of the routine work of the RDC, but is 
an analysis especially done for our needs and proposed contents (see Fig. S1 in the supplementary material for 
study flow chart).
Ethical aspects and study oversight. As described above, the investigators had no access to data of 
individual patients, but only to aggregated results provided by the RDC. Thus, approval by an ethics commit-
tee and patients’ informed consent were not required, in accordance with German law. The study was prepared 
according to STROBE recommendations.
Diagnosis and procedural codes. In the year 2004, diagnosis- and procedure-related remuneration sys-
tem was introduced in Germany with the German Diagnosis Related Groups (G-DRG) system. Data about 
patients’ diagnoses were gathered by the RDC of the Federal Statistical Office and the Statistical Offices of the 
federal states in Wiesbaden (Germany). The diagnoses are coded according to the International Classification of 
Diseases and Related Health Problems with German Modification (10th Revision with German Modification-
ICD-10-GM), and the performed patients’ diagnostic, surgical and interventional procedures are coded accord-
ing to the German Procedure Classification (OPS, surgery and procedures codes [Operationen- und Prozedu-
renschlüssel])35,52.
In our study, we included all hospitalizations, which refer to surgical patients undergoing elective primary 
KJR in Germany from the year 2005 to the year 2016. All hospitalized patients with primary KJR were identi-
fied based on the OPS code 5–822, after exclusion of patients with revision-surgery or replacement of existing 
prostheses (OPS-code 5–823) as well as acute fractures (excluding patients with distal femur fracture (ICD-code 
S72.4) and proximal tibia fracture (ICD-code S82.1)52.
Study outcomes. The outcomes of this study were defined as VTE (including deep venous thrombosis or 
thrombophlebitis (DVT, ICD codes I80, I81, I82) and/or PE (ICD code I26)), prolonged hospitalization (of more 
than 14 days) and death from any causes, respectively recorded during hospital stay.
Statistical methods. Descriptive statistics for patient characteristics of KJR patients with and without 
perioperative VTE were provided as median and interquartile range (IQR) or absolute numbers and correspond-
ing percentages. The Mann–Whitney-U test was used to test the continuous variables of the groups regarding 
differences and categorical variables were compared with  chi2 test or Fisher’s exact test, as  appropriate52.
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We analysed total numbers and incidence of VTE events in elective KJR in Germany between the years 2005 
and 2016 and tested for temporal trends of VTE incidence and in-hospital death rate using linear regression 
models. Results are presented as estimated slope beta (β)-estimates and corresponding 95% confidence intervals 
(CI)35.
In addition, we analysed univariate and multivariable logistic regression models in order to detect influences 
regarding possible predictors of VTE events. Furthermore, we analysed the association between VTE and in-
hospital death as well as VTE and prolonged hospitalization (of more than 14 days). These results of our study 
are presented as odds ratio (OR) and 95% CI. Multivariable regression models were adjusted for age, sex, obe-
sity, cancer, coronary artery disease, heart failure, atrial fibrillation/flutter (AF), essential arterial hypertension, 
chronic obstructive pulmonary disease (COPD), acute and chronic renal failure, and diabetes mellitus. These 
covariates were selected a priori since they represent known risk factors for VTE and in-hospital death. The 
software SPSS (version 20.0; SPSS Inc., Chicago, Illinois) was used for computerised analysis. P values of < 0.05 
(two-sided) were considered to be statistically  significant53–56.
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